Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature

NCT04951492 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04951492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04951492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
November 9, 2022
Completion date
October 15, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, prostate adenocarcinoma